Revenue segments as reported by the company.

Sensor and other revenue

Hardware revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Collaborative research and development fee

Selling, general and administrative

Amortization of intangible assets

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

DexCom

DexCom, Inc. is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F. Burd on May 1, 1999 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

DexCom excels in Q4 2022, eyes international expansion and margin growth

DexCom's Q4 2022 showcased robust financials, operational efficiency, and strategic advancements. The company is well-positioned for continued growth in 2023, with a focus on international expansion, marketing investments, and margin optimization.

DexCom excels in Q1, eyes international growth and market expansion

DexCom's strong Q1 performance and strategic initiatives position the company for sustained growth.
Balancing cost management, market expansion, and product enhancements will be crucial for future success.
Opportunities in new markets, user segments, and product improvements offer avenues for continued growth.
Overall, DexCom's focus on innovation and customer-centric strategies bode well for its long-term prospects.

DexCom reports robust Q2 earnings, eyes international expansion and new products

DexCom's Q2 performance reflects strong revenue growth and market momentum, supported by successful product launches and international expansion.
The company's focus on innovation, customer satisfaction, and cost reduction initiatives positions it well for continued success and market leadership.
While facing challenges in customer experience and product adoption, DexCom's strategic strengths and growth opportunities signal a promising outlook for the future.

DexCom achieves record Q3 performance and expands market leadership

DexCom's Q3 performance reflects strong revenue growth, operational efficiency, and strategic market expansion efforts, setting new records in financial metrics.
The company's strengths lie in market leadership, product innovation, and proactive market expansion strategies, supported by a strong brand and organizational culture.
While facing challenges in pricing strategies, timeline for revenue contributions, and distribution accessibility, DexCom is well-positioned to capitalize on opportunities in new markets and product launches.
Overall, DexCom's performance, strengths, and proactive approach to challenges and opportunities position it for sustained growth and market leadership in the medical devices sector.

DexCom excels in Q4 2023, eyes growth through strategic initiatives

DexCom's strong financial performance, product launches, and market expansions in 2023 set a solid foundation for future growth.
Strategic investments, competitive advantages, and a focus on margin progression position DexCom for continued success.
Challenges in reimbursement pathways and market penetration are being addressed, while opportunities in expanding coverage and product enhancements are being pursued.

DexCom excels in Q1 2024, eyes global expansion and innovation

DexCom's strong financial performance, strategic market expansions, and product innovations position the company for continued growth and success.
While facing challenges in market penetration and product adoption timelines, DexCom's focus on user experience and healthcare outcomes remains a key strength.
Opportunities lie in international market expansion, product differentiation, and leveraging sensor technology for improved patient care and business growth.

DexCom reports 15% revenue growth but lowers full-year guidance

DexCom faced challenges in customer additions and revenue per customer in the U.S. and below-expectation international performance. Despite this, they reported 15% revenue growth and lowered full-year revenue guidance to 11%-13% organic growth.

DexCom meets revenue targets, Stelo launch successful, challenges ahead

DexCom's Q3 performance met expectations with growth in key areas.
Strong market reception for Stelo presents revenue and growth opportunities.
Challenges exist in managing differing customer expectations and sensor performance.
Opportunities lie in expanding international markets and enhancing customer experiences.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San Diego, CA.

Plenty of businesses, such as PepsiCo Inc. NYSE: PEP and Walmart Inc. NYSE: WMT, have been under the microscope on fears of potential earnings decreases due to growing use of products like Novo Nordisk A/S' NYSE: NVO Ozempic, and similar drugs made by Eli Lilly & Co. NYSE: LLY.

Is the Ozempic-Driven DexCom Selloff Overdone?

NVIDIA

Tesla

When stock-market volatility picks up, investors tend to gravitate to outperforming companies that have enacted stock splits. Nine high-profile companies have conducted forward-stock splits since the start of July 2021.

3 Stock-Split Stocks With 110% to 696% Upside, According to Select Wall Street Analysts and Pundits

Baxter

Penumbra

Insulet

ResMed

Zimmer Biomet Hlds

Some investors have worried that new weight-loss drugs could undermine demand for some medical devices.

6 Medical Device Stocks Primed to Bounce Back

Edwards Lifesciences

iShares U.S. Medical Devices ETF

Inspire Medical Systems Inc

Intuitive Surgical

Eli Lilly

Novo Nordisk

September-quarter earnings among medical-device makers may prove better than expected in the age of weight-loss drugs.

MedTech Earnings in the Age of Ozempic May Not Be That Bad

The dramatic weight loss resulting from a new breed of diabetes medication has weighed on DexCom stock. As with all things, however, the devil is in the details.

Why DexCom Stock Rallied on Monday

DexCom's (DXCM) G7 CGM System (launched in Canada) is expected to combine simplicity and power, thereby providing a better way to manage diabetes.

DexCom (DXCM) to Launch Latest CGM System G7 in Canada

While stocks are taking a breather from their recent run, a bull market is on the horizon. Investor interest in stock-split stocks continues, as these stocks have historically generated strong gains over extended periods.

A Bull Market Is Coming: 2 Magnificent Stock-Split Growth Stocks That Could Soar 40% and 51%, According to Wall Street

BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, announced today that its next-generation Dexcom G7 Continuous Glucose Monitoring (CGM) System will be available on October 10, 2023, for Canadians living with all types of diabetes ages two and older, including those who are pregnant. Its introduction brings the most accurate CGM on the market*,1 to Canadians, offering users a new.

Next-Generation Dexcom G7 Continuous Glucose Monitoring System Now Available in Canada

Tandem Diabetes Care

In recent months, diabetes stocks have retreated sharply, partly due to the increased popularity of the weight-loss drug Semaglutide. Some have contended that Semaglutide will greatly reduce the number of people suffering from diabetes in America.

Glucose Game-Changers: 3 Diabetes Stocks to Grab on the Downturn

Wall Street says insulin pump maker Insulet and Tandem Diabetes, as well as glucose-monitor maker DexCom, look ready to rise after pressure from Novo Nordisk's Wegovy and Eli Lilly.

Weight-Loss-Drug Stock Sting May Be Easing for Device Makers

SAN DIEGO--(BUSINESS WIRE)---- $DXCM #COMISAIR--Dexcom Solidifies Global Leadership in Continuous Glucose Monitoring with New Clinical Data Presented at EASD.

Dexcom Solidifies Global Leadership in Continuous Glucose Monitoring With New Clinical Data Presented at EASD

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its third quarter 2023 financial results after market close on Thursday, October 26, 2023. Management will hold a conference call to review the company's third quarter 2023 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and wil.

Dexcom Schedules Third Quarter 2023 Earnings Release and Conference Call for October 26, 2023 at 4:30 p.m. Eastern Time.

DexCom's (DXCM) CGM systems will make dietary assessment through AI-enabled RxFood app, which automatically interprets food images for calorie count in Canada.

DexCom (DXCM) Partners With RxFood for Automated Dietary Monitoring

Alaska Air Group

Etsy

MGM Resorts

Moderna

SolarEdge Technologies

United Continental Hlds

Outside of a handful of highflying technology stocks, U.S. stocks have been practically flat in 2023, but on Wall Street, some analysts remain as bullish as ever.

Wall Street analysts expect the S&P 500 to rise 19% over the next 12 months. Here are their 10 favorite stocks.

It's been a rough half of the year for the S&P 500 — with it slipping nearly 3%. But that's not stopping analysts from bullish calls.

Analysts Predict A 19% Surge For The S&P 500 Soon — Lifted By 10 Stocks

HCA Healthcare

Bio-Techne

As of September 19, S&P 500 healthcare stocks were down 3.2% for the year. Of the 11 sectors, its year to date (YTD) performance is the second worst only behind utilities.

3 Healthcare Stocks That Should Be on Every Investor's Radar This Fall

Palo Alto Networks

Sirius XM Holdings Inc

A remarkable 30-year bull run for the Nasdaq 100 saw it gain nearly 4,000% by 2020. But, the party came to a screeching halt when the pandemic hit.

3 Unstoppable Nasdaq 100 Stocks Just Waiting to Be Bought

BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, and RxFood Corporation, the leader in AI-driven personalized nutrition assessments, announced today a first-of-its-kind partnership in Canada to introduce an improved digital health solution for those living with diabetes. The next generation RxFood app, featuring Dexcom CGM glucose data integration, is now available to health care.

Dexcom Canada and RxFood Corporation Partner on Industry-Leading, AI-powered Nutrition and Glucose Monitoring Solution for Diabetes Management and Personalized Therapeutic Nutrition

Madrigal Pharmaceuticals

Shares of companies that treat everything from Type 2 diabetes to sleep apnea have been sinking since new weight-loss medications skyrocketed.

Medtech Makers Are the Real Losers From Obesity Drugs

West Pharmaceutical Services

DexCom, Eli Lilly, and West Pharmaceutical Services have been among the hottest healthcare stocks to own over the past decade. These top healthcare companies are in good positions to benefit from even more growth in the future.

3 Healthcare Stocks That Turned $100,000 Into $1 Million in 10 Years

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the launch of the second season of Dexcom U, the first-ever NIL (name, image, likeness) program exclusively for college athletes with diabetes, which had its inaugural season last year. Dexcom U is a unique NIL program that was created in response to a 2022 survey which found that improving representation for people with diabetes can ins.

Dexcom U Kicks off 2023 Season With Expanded Roster of Athletes With Diabetes, Building on First-of-its-Kind NIL Program

DexCom's (DXCM) latest CGM sensor, DexCom ONE, secures reimbursement coverage in France, bringing the real-time CGM sensor to half a million diabetes patients in the country.

DexCom (DXCM) Launches Latest CGM Sensor ONE in France

The notable increase in DexCom's revenues over recent quarters has also contributed to the stock recovery.

Will DexCom Stock Recover To Its Pre-Inflation Shock Highs Of $160?

A Raymond James analyst cut his price target on the specialty medical device maker. It was the second such price target cut so far this month.

Why DexCom Stock Dove by 5% Today

DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.

News for DexCom Stock (DXCM)